Emi Hifumi

Prof. Dr. Emi Hifumi


Research Focus & Metrics

Academic Career Length

28Years (1999-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 May 2016 in Analytical and Bioanalytical Chemistry
Verified
Journal Article
Closed access
PDF file
YKYumi Katayama
Yumi Katayama
TOTakayuki Ohgi
Takayuki Ohgi
YMYoshiharu Mitoma
Yoshiharu Mitoma
EHEmi Hifumi
Emi Hifumi
NENaoyoshi Egashira
Naoyoshi Egashira

1 January 2000 in Applied Biochemistry and Biotechnology
Verified
Journal Article
Closed access
PDF file
EHEmi Hifumi
Emi Hifumi
YOYoshiko Okamoto
Yoshiko Okamoto
TUTaizo Uda
Taizo Uda

1 July 2013 in Journal of Biological Chemistry
Verified
Journal Article
Open access
PDF file
EHEmi Hifumi
Emi Hifumi
NFNaoko Fujimoto
Naoko Fujimoto
MAMitsue Arakawa
Mitsue Arakawa
ESEri Saito
Eri Saito
SMShingo Matsumoto
Shingo Matsumoto
TUTaizo Uda
Taizo Uda
Human antibody light chains belonging to subgroup II of germ line genes were amplified by a seminested PCR technique using B-lymphocytes taken from a human adult infected with influenza virus. Each gene of the human light chains was transferred into the Escherichia coli system. The recovered light chain was highly purified using a two-step purification system. Light chain 22F6 showed interesting catalytic features. The light chain cleaved a peptide bond of synthetic peptidyl-4-methyl-coumaryl-7-amide (MCA) substrates, such as QAR-MCA and EAR-MCA, indicating amidase activity. It also hydrolyzed a phosphodiester bond of both DNA and RNA. From the analysis of amino acid sequences and molecular modeling, the 22F6 light chain possesses two kinds of active sites as amidase and nuclease in close distances. The 22F6 catalytic light chain could suppress the infection of influenza virus type A (H1N1) of Madin-Darby canine kidney cells in an in vitro assay. In addition, the catalytic light chain clearly inhibited the infection of the influenza virus of BALB/c mice via nasal administration in an in vivo assay. In the experiment, the titer in the serum of the mice coinfected with the 22F6 light chain and H1N1 virus became considerably lowered compared with that of 22F6-non-coinfected mice. Note that the catalytic light chain was prepared from human peripheral lymphocyte and plays an important role in preventing infection by influenza virus. Considering the fact that the human light chain did not show any acute toxicity for mice, our procedure developed in this study must be unique and noteworthy for developing new drugs.

20 February 2015 in The FASEB Journal
Verified
Journal Article
Open access
PDF file
EHEmi Hifumi
Emi Hifumi
MAMitsue Arakawa
Mitsue Arakawa
SMShingo Matsumoto
Shingo Matsumoto
TYTatsuhiro Yamamoto
Tatsuhiro Yamamoto
YKYoshiki Katayama
Yoshiki Katayama
TUTaizo Uda
Taizo Uda
Catalytic antibodies have exhibited interesting functions against some infections viruses such as HIV, rabies virus, and influenza virus in vitro as well as in vivo. In some cases, a catalytic antibody light chain takes on several structures from the standpoint of molecular size (monomer, dimer, etc.) and/or isoelectronic point. In this study, we prepared a monomeric 23D4 light chain by mutating the C‐terminal Cys to Ala of the wild‐type. The mutated 23D4 molecule took a simple monomeric form, which could hydrolyze synthetic 4‐methyl‐coumaryl‐7‐amide substrates and a plasmid DNA. Because the monomeric 23D4 light chain suppressed the infection of influenza virus A/Hiroshima/37/2001 in an in vitro assay, the corresponding experiments were conducted in vivo , after the virus strain (which was taken from a human patient) was successfully adapted into BALB/cN Sea mice. In the experiments, a mixture of the monomeric 23D4 and the virus was nasally administered 1) with preincubation and 2) without preincubation. As a result, the monomeric 23D4 clearly exhibited the ability to suppress the influenza virus infection in both cases, indicating a potential drug for preventing infection of the influenza A virus.— Hifumi, E., Arakawa, M., Matsumoto, S., Yamamoto, T., Katayama, Y., Uda, T. Biochemical features and antiviral activity of a monomeric catalytic antibody light‐chain 23D4 against influenzaAvirus. FASEB J. 29, 2347‐2358 (2015). www.fasebj.org

9 August 2002 in Analytical Sciences
Verified
Journal Article
Closed access
EHEmi Hifumi
Emi Hifumi
NKNaruhiko Kubota
Naruhiko Kubota
YNYoshiyuki Niimi
Yoshiyuki Niimi
KSKosuke Shimizu
Kosuke Shimizu
NENaoyoshi Egashira
Naoyoshi Egashira
TUTaizo Uda
Taizo Uda
Highly sensitive detection of proteins in serum becomes difficult in some cases during surface plasmon resonance (SPR) measurements, because some ingredients in the serum hugely enhance non-specific reactions on the sensing chip of SPR. It is well recognized that the antibody against core protein p24 of HIV in serum is one of the most important proteins in the accurate diagnosis of infection with HIV. In this study, we could attain the accurate detection of anti p24 antibody in human serum by eliminating the serious effects of the ingredients in serum on the measurement of SPR by employing these procedures: 1) blocking the gold surface of the sensing chip with human serum and 2) heating the serum sample at 56 degrees C for 30 min. Without these treatments, the signal of SPR was considerably suppressed on the measurements of the anti p24 antibody which contained human serum, making the accurate detection difficult. However, with introducing the above two treatments, the sensing of anti p24 antibody in human serum was improved, while a small non-specific reaction was still observed. By removing the non-specific reaction caused by the ingredients in the serum, we could accurately measure the antibody for p24 in human serum sample over the range from 1 to 20 micrograms/ml.

2 November 2015 in The FASEB Journal
Verified
Journal Article
Open access
PDF file
EHEmi Hifumi
Emi Hifumi
SMShingo Matsumoto
Shingo Matsumoto
HNHiroki Nakashima
Hiroki Nakashima
SIShogo Itonaga
Shogo Itonaga
MAMitsue Arakawa
Mitsue Arakawa
TUTaizo Uda
Taizo Uda
Along with the development of antibody drugs and catalytic antibodies, the structural diversity (heterogeneity) of antibodies has been given attention. For >20 yr, detailed studies on the subject have not been conducted, because the phenomenon presents many difficult and complex problems. Structural diversity provides some (or many) isoforms of an antibody distinguished by different charges, different molecular sizes, and modifications of amino acid residues. For practical use, the antibody and the subunits must have a defined structure. In recent work, we have found that the copper (Cu) ion plays a substantial role in solving the diversity problem. In the current study, we used several catalytic antibody light chains to examine the effect of the Cu ion. In all cases, the different electrical charges of the molecule converged to a single charge, giving 1 peak in cation‐exchange chromatography, as well as a single spot in 2‐dimensional gel electrophoresis. The Cu‐binding site was investigated by using mutagenesis, ultraviolet‐visible spectroscopy, atomic force microscope analysis, and molecular modeling, which suggested that histidine and cysteine residues close to the C‐terminus are involved with the binding site. The constant region domain of the antibody light chain played an important role in the heterogeneity of the light chain. Our findings may be a significant tool for preparing a single defined, not multiple, isoform structure.—Hifumi, E., Matsumoto, S., Nakashima, H., Itonaga, S., Arakawa, M., Katayama, Y., Kato, R., Uda T. A novel method of preparing the monoform structure of catalytic antibody light chain. FASEB J. 30, 895–908 (2016). www.fasebj.org